Recent research has shown that patients who test positive for PLA2R antibodies experiencing a reduced rate of natural remission compared to individuals who test negative for antibodies (33).Standard therapies, including corticosteroids and cyclophosphamide, may not achieve immunologic remission in approximately 10% of patients with membranous nephropathy associated with anti-phospholipase A2 receptor antibody (aPLA2R). This evidence concerns the gene PLA2R1 and membranous glomerulonephritis.